Oncotarget

Research Papers:

Multiplexed targeted mass spectrometry assays for prostate cancer-associated urinary proteins

Tujin Shi, Sue-Ing Quek, Yuqian Gao, Carrie D. Nicora, Song Nie, Thomas L. Fillmore, Tao Liu, Karin D. Rodland, Richard D. Smith, Robin J. Leach, Ian M. Thompson, Elizabeth A. Vitello, William J. Ellis, Alvin Y. Liu and Wei-Jun Qian _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:101887-101898. https://doi.org/10.18632/oncotarget.21710

Metrics: PDF 1109 views  |   HTML 1657 views  |   ?  


Abstract

Tujin Shi1, Sue-Ing Quek2,3,6, Yuqian Gao1, Carrie D. Nicora1, Song Nie1, Thomas L. Fillmore4, Tao Liu1, Karin D. Rodland1, Richard D. Smith1, Robin J. Leach5, Ian M. Thompson5, Elizabeth A. Vitello2,3, William J. Ellis2, Alvin Y. Liu2,3 and Wei-Jun Qian1

1Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA

2Department of Urology, University of Washington, Seattle, WA, USA

3Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA

4Environmental Molecular Sciences Laboratory, Pacific Northwest National Laboratory, Richland, WA, USA

5Department of Urology and the Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

6Present address: Singapore Polytechnic, Center for Biomedical and Life Sciences T11A-412 (level 4), Singapore

Correspondence to:

Wei-Jun Qian, email: weijun.qian@pnnl.gov

Alvin Y. Liu, email: aliu@uw.edu

Keywords: secreted protein biomarkers; prostate cancer detection; prostate cancer; targeted mass spectrometry; selected reaction monitoring

Received: May 05, 2017    Accepted: August 04, 2017    Published: October 09, 2017

ABSTRACT

Biomarkers for effective early diagnosis and prognosis of prostate cancer are still lacking. Multiplexed assays for cancer-associated proteins could be useful for identifying biomarkers for cancer detection and stratification. Herein, we report the development of sensitive targeted mass spectrometry assays for simultaneous quantification of 10 prostate cancer-associated proteins in urine. The diagnostic utility of these markers was evaluated with an initial cohort of 20 clinical urine samples. Individual marker concentration was normalized against the measured urinary prostate-specific antigen level as a reference of prostate-specific secretion. The areas under the receiver-operating characteristic curves for the 10 proteins ranged from 0.75 for CXL14 to 0.87 for CEAM5. Furthermore, MMP9 level was found to be significantly higher in patients with high Gleason scores, suggesting a potential of MMP9 as a marker for risk level assessment. Taken together, our work illustrated the feasibility of accurate multiplexed measurements of low-abundance cancer-associated proteins in urine and provided a viable path forward for preclinical verification of candidate biomarkers for prostate cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 21710